HR 8454 · 117th Congress 2021–2023, ended

Medical Marijuana and Cannabidiol Research Expansion Act

Latest action · Dec 2, 2022 Became Public Law No: 117-215.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJul 21, 2022
  2. Passed HouseJul 26, 2022
  3. Passed SenateNov 16, 2022
  4. To the PresidentNov 29, 2022
  5. Became lawDec 2, 2022Public Law 117-215

Summary

Medical Marijuana and Cannabidiol Research Expansion Act

This act establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the act directs the Drug Enforcement Administration (DEA) to follow procedures specified in the act to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the act includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.

Recorded votes 1

Newest first. Open one to see how every member voted.

Roll callQuestionResultDate
House 392Passed325–95Jul 26, 2022

Cosponsors 10

Members who signed on, in the order they did. Signatures ran from Jul 21, 2022 to Jul 22, 2022; 6 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
R-MDAndy HarrisOriginalJul 21, 2022
R-OHDavid P. JoyceOriginalJul 21, 2022
D-COEd PerlmutterOriginalJul 21, 2022
D-DCEleanor Holmes NortonOriginalJul 21, 2022
R-VAH. Morgan GriffithOriginalJul 21, 2022
R-SCNancy MaceOriginalJul 21, 2022
D-CABarbara LeeJul 22, 2022
D-NHChris PappasJul 22, 2022
D-MIDebbie DingellJul 22, 2022
D-TNSteve CohenJul 22, 2022

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Jul 21, 2022
HouseJudiciary Committee
Referred Jul 21, 2022

Actions 15

Everything that happened, newest first.

  1. Dec 2, 2022Signed by President.
  2. Dec 2, 2022Became Public Law No: 117-215.
  3. Nov 29, 2022Presented to President.
  4. Nov 17, 2022Message on Senate action sent to the House.
  5. Nov 16, 2022Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S6746-6747)
  6. Jul 27, 2022Received in the Senate, read twice.
  7. Jul 26, 2022Mr. Pallone moved to suspend the rules and pass the bill, as amended.
  8. Jul 26, 2022Considered under suspension of the rules. (consideration: CR H7120-7124)
  9. Jul 26, 2022DEBATE - The House proceeded with forty minutes of debate on H.R. 8454.
  10. Jul 26, 2022At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
  11. Jul 26, 2022Considered as unfinished business. (consideration: CR H7145-7146)
  12. Jul 26, 2022Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392). (text: CR H7120-7122)
  13. Jul 26, 2022Motion to reconsider laid on the table Agreed to without objection.
  14. Jul 21, 2022Introduced in House
  15. Jul 21, 2022Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

In the Congressional Record 3

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S6736, S6746Charles E. Schumer D-NYNov 16, 2022
HouseDebate and remarks H7120–H7124Text printed H7120–H7122Recorded votes H7145enactLists H7146Votes recorded by proxy on H.R. 8454, Medical Marijuana and Cannabidiol Research Expansion ActNotices H7163Estimated budget effects of H.R. 8454, Medical Marijuana and Cannabidiol Research Expansion ActAndy Harris R-MD, Anna G. Eshoo D-CA, Earl Blumenauer D-OR, Earl L. "Buddy" Carter R-GA, Frank Pallone, Jr. D-NJ, H. Morgan Griffith R-VA, John A. Yarmuth D-KYJul 26, 2022
HouseLists H7066H.R. 8454–8484—Jul 21, 2022

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article 1, Section 8, Clause 3 of the U.S. Constitution

The sponsor’s statement, as printed in the Congressional Record, vol. 168, no. 121, July 21, 2022, page H7066.

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 253Cannabidiol and Marihuana Research Expansion ActRelated billMar 28, 2022

Titles 6

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To expand research on cannabidiol and marijuana, and for other purposes.
Short Titles as Passed Senate
Medical Marijuana and Cannabidiol Research Expansion Act
Short Titles as Enacted
Medical Marijuana and Cannabidiol Research Expansion Act
Short Title(s) as Introduced
Medical Marijuana and Cannabidiol Research Expansion Act
Short Title(s) as Passed House
Medical Marijuana and Cannabidiol Research Expansion Act
Short Titles from ENR (Enrolled) bill text
Medical Marijuana and Cannabidiol Research Expansion Act

Subjects

Assigned by the Library of Congress. Policy area: Crime and Law Enforcement.

Text 4

Each version as it was printed, newest first.

  1. —Enrolled Bill
  2. Jul 27, 2022Received in Senate
  3. Jul 26, 2022Engrossed in House
  4. Jul 21, 2022Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.